- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05576623
Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
A Phase I/II (Single Center, Open, Phase I and Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Phase II) Trial to Evaluate the Safety and Immunogenicity of the AdCLD-CoV19-1 OMI Administered as a Booster to Healthy Adults Aged 19 Years Old and Above
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Gaeun Park, PM
- Email: gepark@cellid.co.kr
Study Contact Backup
- Name: Subin Kwon, PA
- Phone Number: +8210.8890.3907
- Email: sbkwon@cellid.co.kr
Study Locations
-
-
-
Gyeonggi-do, Korea, Republic of
- Korea University Ansan Hospital
-
Gyeonggi-do, Korea, Republic of
- Hallym University Dongtan Sacred Heart Hospital
-
Gyeonggi-do, Korea, Republic of
- The Catholic University Of Korea St. Vincent's Hospital
-
Incheon, Korea, Republic of
- Inha University Hospital
-
Incheon, Korea, Republic of
- Gachon University Gil Medical Center
-
Seoul, Korea, Republic of
- Korea University Guro Hospital
-
Seoul, Korea, Republic of
- Hallym University Kangnam Sacred Heart Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
(Part A) Individual aged between 19-64 years old and willing to provide written informed consent to participate study voluntarily.
(Part B) Individual aged 19 years and above and willing to provide written informed consent to participate study voluntarily.
Individual fall under one or more of the following;
- Those who have been at least 16 weeks (112 days) and less than 48 weeks (336 days) without additional COVID-19 vaccination since the last COVID-19 vaccination.
- Those who have been at least 16 weeks (112 days) or more and less than 48 weeks (336 days) since the release of quarantine due to COVID-19 confirmation.
- Individual with body mass index (BMI) of 30.0 kg/m2 or less at screening visit.
- Individual who agrees with using an effective birth control method for at least 4 weeks before the screening and during the study period.
- Individual who agrees not to donate or transfuse blood (including whole blood, plasma components, platelet components, and platelet plasma components) during the study period.
Exclusion Criteria:
- Individual who has history of COVID-19 or is considered infected within 16 weeks (112 days) prior to administration of investigational product.
- Individual who has received other COVID-19 vaccine within 16 weeks (112 days) prior to administration of investigational product.
- Individual who has been in close contact with a COVID-19 infected person, or has been classified as a confirmed or suspected COVID-19 patient within 14 days prior to administration of investigational product.
- Individual determined to be clinically significantly abnormal by the screening outcome based on laboratory evaluations, electrocardiogram (ECG) and Chest X-ray.
- Individual who has ant results of positive to HIV test, hepatitis B test, and hepatitis C test on screening.
- Acute febrile illness with 38°C and above, or any suspected infectious diseases, or symptoms similar to COVID-19 (cough, shortness of breathe, chills, myalgia, headache, sore throat, loss of taste/smell, etc.) within 3 days prior to administration of investigational product.
Any serious medical or psychiatric disease which in opinion of investigator judges unable to participate
- Respiratory diseases: Asthma, Chronic Obstructive Lung Disease (COPD), active or latent tuberculosis which require medication, or individual who has received treatment due to worsening of the respiratory disease within 5 years prior to administration of investigational product.
- Serious cardiovascular diseases: Congestive heart failure, coronary artery disease, myocardial infarction, uncontrolled hypertension, myocarditis, pericarditis, etc.
- Neurologic diseases: Epilepsy, seizure within 3 years, migraine, stroke, encephalopathy, Guillain-Barre Syndrome, encephalomyelitis, acute transverse myelitis, etc.
- Malignant cancer diagnosed within the past 5 years (skin basal cell and squamous cell carcinoma are excluded).
- Immune function disorders including autoimmune hypothyroidism, psoriasis.
- Auto-immune diseases.
- History of dependently administering psychotropic drugs or narcotic painkillers within 24 weeks prior to administration of investigational product, or psychiatric disease or behavioral impairment that, in the opinion of the investigator, could interfere with the participant's ability to participate in the trial.
- Other hepatobiliary, renal, endocrine, urinary tract, muscular skeletal diseases which the investigator considers clinically significant.
- History of splenectomy.
- History of SARS-CoV or MERS-CoV infection.
- Known history of allergic or hypersensitivity to the components of investigational product.
- Known history of serious adverse reactions, allergies or hypersensitivity related to vaccination.
- History of urticaria within 5 years prior to administration of investigational product.
- Individual with history of bleeding diathesis or thrombocytopenia, or history of severe bleeding or bruising after intramuscular or intravenous injection, or is receiving an anticoagulant (Those who receive low dose aspirin (less than 100mg/day) are not excluded).
- Individual with hereditary or idiopathic angioneurotic edema.
- Individual with solid organ or bone marrow transplantation.
- Individual who is suspected or with history of substance abuse and alcohol abuse within 24 weeks prior to administration of investigational product.
- History of SARS-CoV or MERS-CoV vaccination.
- History of licensed drug for COVID-19 treatment or prevention aside from COVID-19 vaccine within 52 weeks prior to administration of investigational product.
Use of immunosuppressive or chronic use of systemic steroids within 6 weeks prior to administration of investigational product (External steroids, nasal spray and inhalants are allowed).
- Immunosuppressive: Azathioprine, Cyclosporine, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus, Cyclophosphamide, 6-Mercaptopurine, Methotrexate, Rapamycin, Leflunomide, etc.
- Chronic steroid: >10 mg/day prednisone equivalent for periods exceeding 14 days)
- Individuals who has administered other investigational product or device within 24 weeks prior to screening visit.
- Individual concomitantly enrolled or scheduled to be enrolled in another trial (including follow-up period).
- Individual vaccinated or planned vaccination within 28 days prior and after the administration of investigational product.
- Receipt of immunoglobulin or blood-derived products within 12 weeks prior to administration of investigational product.
- Individual with scheduled surgery during the study period.
- Pregnant or lactating women.
Individual directly related to the investigator and meets the following conditions:
- Personnel relationship or subordinate-superior relationship (employees of the investigator's department, staffs of this trial)
- Students or researchers in the immediate department of the school to which the investigator belongs (e.g., medical university)
- Individual who is unfit for this study for any other reason in judgement of investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1 dose of AdCLD-CoV19-1 OMI (Part A)
Group in Part A will receive 1 dose of AdCLD-CoV19-1 OMI
|
20 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
|
EXPERIMENTAL: 1 dose of AdCLD-CoV19-1 OMI (Part B)
Group 1 in Part B will receive 1 dose of AdCLD-CoV19-1 OMI
|
250 participants will receive investigational product (AdCLD-CoV19-1 OMI) via intramuscular injection in the deltoid muscle
|
PLACEBO_COMPARATOR: Placebo (Part B)
Group 2 in Part B will receive 1 dose of placebo
|
50 participants will receive placebo via intramuscular injection in the deltoid muscle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of immediate adverse events (AE)
Time Frame: Within 30 minutes post dose injection
|
Proportion of immediate AE within 30 minutes post dose injection.
|
Within 30 minutes post dose injection
|
Proportion of solicited local and systemic AE
Time Frame: Within 7 days (Days 0 - 6) post dose injection
|
Proportion of solicited local and systemic AEs within 7 days post dose injection.
Local AEs at the site of injection: Pain, tenderness, erythema/redness, swelling/induration, pruritis.
Systemic AEs: Fever, fatigue/general weakness, chill, headache, myalgia, arthralgia, diarrhea, nausea/vomiting, abdominal pain, mucocutaneous reaction/rash, urticaria, dizziness, cough, dyspnea.
|
Within 7 days (Days 0 - 6) post dose injection
|
Proportion of unsolicited AE
Time Frame: Within 28 days post dose injection
|
Proportion of unsolicited AEs within 28 days post dose injection.
Unsolicited AEs are all other adverse events (those that do not fall under the categories of solicited AEs).
|
Within 28 days post dose injection
|
Proportion of SAE
Time Frame: Throughout the study duration, 12 months post dose injection
|
Proportion of any SAE from the administration throughout the entire study.
An AE or suspected adverse reaction is considered "serious": Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require intervention to prevent one of the other outcomes listed above.
|
Throughout the study duration, 12 months post dose injection
|
Proportion of Adverse Event Of Special Interest (AESI)
Time Frame: Throughout the study duration, 12 months post dose injection
|
Proportion of any AESI from the administration throughout the entire study.
AESI are categorized into 1) AESIs included because they are seen with COVID-19 Disease, 2) AESI included because they have a proven or theoretical association with immunization in general, 3) AESI included because they have a proven or theoretical association with specific vaccine platform(s).
|
Throughout the study duration, 12 months post dose injection
|
Proportion of Medically-Attended Adverse Events (MAAE)
Time Frame: Throughout the study duration, 12 months post dose injection
|
Proportion of any MAAE from the administration throughout the entire study.
Medically-attended AEs are AEs with medically-attended visits including hospital, emergency room, or other visits to or from medical personnel for any reason.
Routine study visits will not be considered medically attended visits.
|
Throughout the study duration, 12 months post dose injection
|
Proportion of clinically significant changes in clinical safety laboratory parameters
Time Frame: At 7, 14, 28 days post dose injection
|
Proportion of clinically significant changes in clinical safety laboratory parameters at 7, 14, 28 days post dose injection.
|
At 7, 14, 28 days post dose injection
|
Proportion of participants achieving seroresponse of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4 weeks post dose injection (Neutralizing antibody)
Time Frame: At 2, 4 weeks post dose injection
|
Proportion of participants achieving seroresponse (SR defined as at least 2-fold increase from baseline) of wild-type virus neutralizing antibody titer from baseline to 2, 4 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 2, 4 weeks post dose injection
|
Geometric Mean Titer of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4 weeks post dose injection (Neutralizing antibody)
Time Frame: At 2, 4 weeks post dose injection
|
Geometric Mean Titer (GMT) of neutralizing antibody to the SARS-CoV-2 B.1.1.529
measured by wild-type virus neutralization assay from baseline to 2, 4 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 2, 4 weeks post dose injection
|
Geometric Mean Fold Rise of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4 weeks post dose injection (Neutralizing antibody)
Time Frame: At 2, 4 weeks post dose injection
|
Geometric Mean Fold Rise (GMFR) of neutralizing antibody to the SARS-CoV-2 B.1.1.529
measured by wild-type virus neutralization assay from baseline to 2, 4 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 2, 4 weeks post dose injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants achieving seroresponse of 1 dose of AdCLD-CoV19-1 OMI from baseline to 12, 26, 52 weeks post dose injection (Neutralizing antibody)
Time Frame: At 12, 26, 52 weeks post dose injection
|
Proportion of participants achieving seroresponse (SR defined as at least 2-fold increase from baseline) of wild-type virus neutralizing antibody titer from baseline to 12, 26, 52 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 12, 26, 52 weeks post dose injection
|
Geometric Mean Titer of 1 dose of AdCLD-CoV19-1 OMI from baseline to 12, 26, 52 weeks post dose injection (Neutralizing antibody)
Time Frame: At 12, 26, 52 weeks post dose injection
|
Geometric Mean Titer (GMT) of neutralizing antibody to the SARS-CoV-2 B.1.1.529
measured by wild-type virus neutralization assay from baseline to 12, 26, 52 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 12, 26, 52 weeks post dose injection
|
Geometric Mean Fold Rise of 1 dose of AdCLD-CoV19-1 OMI from baseline to 12, 26, 52 weeks post dose injection (Neutralizing antibody)
Time Frame: At 12, 26, 52 weeks post dose injection
|
Geometric Mean Fold Rise (GMFR) of neutralizing antibody to the SARS-CoV-2 B.1.1.529
measured by wild-type virus neutralization assay from baseline to 12, 26, 52 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 12, 26, 52 weeks post dose injection
|
Proportion of participants achieving seroresponse of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4, 12, 26, 52 weeks post dose injection (ELISA)
Time Frame: At 2, 4, 12, 26, 52 weeks post dose injection
|
Proportion of participants achieving seroresponse (SR defined as at least 2-fold increase from baseline) of SARS-CoV-2 B.1.1.529
Spike-binding ELISA IgG antibody from baseline to 2, 4, 12, 26, 52 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 2, 4, 12, 26, 52 weeks post dose injection
|
GMT of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4, 12, 26, 52 weeks post dose injection (ELISA)
Time Frame: At 2, 4, 12, 26, 52 weeks post dose injection
|
GMT of SARS-CoV-2 B.1.1.529
Spike-binding ELISA IgG antibody from baseline to 2, 4, 12, 26, 52 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 2, 4, 12, 26, 52 weeks post dose injection
|
GMFR of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4, 12, 26, 52 weeks post dose injection (ELISA)
Time Frame: At 2, 4, 12, 26, 52 weeks post dose injection
|
GMFR of SARS-CoV-2 B.1.1.529
Spike-binding ELISA IgG antibody from baseline to 2, 4, 12, 26, 52 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 2, 4, 12, 26, 52 weeks post dose injection
|
Cell Mediated Immunity (CMI) of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 26, 52 weeks post dose injection (Proportion of responders by Interferon-γ (IFN-γ) ELISpot)
Time Frame: At 2, 26, 52 weeks post dose injection
|
Proportion of responders as measured by Interferon-γ (IFN-γ) ELISpot from baseline to 2, 26, 52 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 2, 26, 52 weeks post dose injection
|
Cell Mediated Immunity (CMI) of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 26, 52 weeks post dose injection (Median spot forming units by Interferon-γ (IFN-γ) ELISpot)
Time Frame: At 2, 26, 52 weeks post dose injection
|
Median spot forming units as measured by Interferon-γ (IFN-γ) ELISpot from baseline to 2, 26, 52 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 2, 26, 52 weeks post dose injection
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SRR, GMT, GMFR of 1 dose of AdCLD-CoV19-1 OMI from baseline to 4 weeks post dose injection (Neutralizing antibody)
Time Frame: At 4 weeks post dose injection
|
SRR, GMT, GMFR of neutralizing antibody to the SARS-CoV-2 Wuhan strain and Variants of concern (VOC) measured by wild-type virus neutralization assay from baseline to 4 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI.
|
At 4 weeks post dose injection
|
SRR, GMT, GMFR of 1 dose of AdCLD-CoV19-1 OMI from baseline to 2, 4 weeks post dose injection (Neutralizing antibody) according to the recipients features.
Time Frame: At 2, 4 weeks post dose injection
|
SRR, GMT, GMFR of neutralizing antibody to the SARS-CoV-2 B.1.1.529 measured by wild-type virus neutralization assay from baseline to 2, 4 weeks post dose injection induced by 1 dose of AdCLD-CoV19-1 OMI according to the recipients features as follows;
|
At 2, 4 weeks post dose injection
|
Number of severe COVID-19 cases from 2 weeks post dose injection to the end of study period
Time Frame: Throughout the study duration, 12 months post dose injection
|
Number of severe COVID-19 cases using Rapid Antigen Test Kit or RT-PCR from 2 weeks post dose injection to the end of study period with one or more symptoms of COVID-19 including:
|
Throughout the study duration, 12 months post dose injection
|
Number of hospitalization due to COVID-19 from 2 weeks post dose injection to the end of study period
Time Frame: Throughout the study duration, 12 months post dose injection
|
Number of hospitalization due to COVID-19 confirmed by using Rapid Antigen Test Kit or RT-PCR from 2 weeks post dose injection to the end of study period.
|
Throughout the study duration, 12 months post dose injection
|
Number of death due to COVID-19 from 2 weeks post dose injection to the end of study period
Time Frame: Throughout the study duration, 12 months post dose injection
|
Number of death due to COVID-19 confirmed by using Rapid Antigen Test Kit or RT-PCR from 2 weeks post dose injection to the end of study period.
|
Throughout the study duration, 12 months post dose injection
|
Number of virologically-confirmed COVID-19 cases from 2 weeks post dose injection to the end of study period
Time Frame: Throughout the study duration, 12 months post dose injection
|
Number of virologically-confirmed COVID-19 cases using Rapid Antigen Test Kit or RT-PCR from 2 weeks post dose injection to the end of study period with one or more symptoms of COVID-19 including fever, chill, cough, shortness of breath, fatigue, myalgia, headache, loss of taste or smell, pharyngitis, rhinorrhea, nausea, vomiting, diarrhea.
|
Throughout the study duration, 12 months post dose injection
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- COVENT-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on AdCLD-CoV19-1 OMI (Part A)
-
Cellid Co., Ltd.Not yet recruitingCOVID-19 | VaccinesKorea, Republic of
-
Cellid Co., Ltd.CompletedCovid19Korea, Republic of
-
Cellid Co., Ltd.International Vaccine InstituteTerminated
-
AstraZenecaAcerta Pharma, LLCCompletedBioavailability | B-cell Lymphoid CancerUnited States
-
PfizerCompletedRheumatoid Arthritis | Healthy VolunteersUnited States
-
Bukwang PharmaceuticalActive, not recruitingParkinson Disease | DyskinesiasUnited States
-
Kanyos Bio, Inc., a wholly-owned subsidiary of...PfizerRecruitingCeliac DiseaseUnited States, Australia, New Zealand
-
HvivoPfizerRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.CompletedSmall Cell Lung CancerChina
-
AstraZenecaCompletedCardiovascular Disease | Healthy Male SubjectsUnited Kingdom